Skip to content
Home/Companies/Healthcare / Biotech/ProQR Therapeutics
ProQR Therapeutics

ProQR Therapeutics

Healthcare / Biotech·Netherlands·Active·8yr hold
Entry
2018
Hold
8yr
Status
Active

Who owns ProQR Therapeutics?

ProQR Therapeutics is currently owned by Sofinnova Partners through Sofinnova Capital IX (2018 vintage), since 2018.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital IX · 2018 · Life Sciences VC

Key facts

HQNetherlands
SectorHealthcare / Biotech
Websitewww.proqr.com

More from Sofinnova Capital IX

Other portfolio companies in the same fund.

Asceneuron
Active
BiotechSwitzerland· 2020
CorVent Medical
CorVent Medical
Active
MedTechUS· 2020
Genespire
Genespire
Active
BiotechItaly· 2020
Nitrase Therapeutics
Nitrase Therapeutics
Active
BiotechUS· 2020
Noema Pharma
Noema Pharma
Exited 2022
BiotechSwitzerland· 2020
to
Pi-Cardia
Pi-Cardia
Active
MedTechIsrael· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track ProQR Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy ProQR Therapeutics?

2 strategic and 118financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on ProQR Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue